-
Je něco špatně v tomto záznamu ?
Modulation of the antagonistic properties of an insulin mimetic peptide by disulfide bridge modifications
M. Lubos, J. Pícha, I. Selicharová, J. Žák, M. Buděšínský, K. Mitrová, L. Žáková, J. Jiráček
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
Grantová podpora
MR/R009066/1
Medical Research Council - United Kingdom
PubMed
36633503
DOI
10.1002/psc.3478
Knihovny.cz E-zdroje
- MeSH
- disulfidy chemie MeSH
- inzulin * metabolismus MeSH
- peptidy chemie MeSH
- receptor inzulinu * MeSH
- Publikační typ
- časopisecké články MeSH
Insulin is a peptide responsible for regulating the metabolic homeostasis of the organism; it elicits its effects through binding to the transmembrane insulin receptor (IR). Insulin mimetics with agonistic or antagonistic effects toward the receptor are an exciting field of research and could find applications in treating diabetes or malignant diseases. We prepared five variants of a previously reported 20-amino acid insulin-mimicking peptide. These peptides differ from each other by the structure of the covalent bridge connecting positions 11 and 18. In addition to the peptide with a disulfide bridge, a derivative with a dicarba bridge and three derivatives with a 1,2,3-triazole differing from each other by the presence of sulfur or oxygen in their staples were prepared. The strongest binding to IR was exhibited by the peptide with a disulfide bridge. All other derivatives only weakly bound to IR, and a relationship between increasing bridge length and lower binding affinity can be inferred. Despite their nanomolar affinities, none of the prepared peptide mimetics was able to activate the insulin receptor even at high concentrations, but all mimetics were able to inhibit insulin-induced receptor activation. However, the receptor remained approximately 30% active even at the highest concentration of the agents; thus, the agents behave as partial antagonists. An interesting observation is that these mimetic peptides do not antagonize insulin action in proportion to their binding affinities. The compounds characterized in this study show that it is possible to modulate the functional properties of insulin receptor peptide ligands using disulfide mimetics.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23010959
- 003
- CZ-PrNML
- 005
- 20230801132728.0
- 007
- ta
- 008
- 230718s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/psc.3478 $2 doi
- 035 __
- $a (PubMed)36633503
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Lubos, Marta $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Praha, Czech Republic
- 245 10
- $a Modulation of the antagonistic properties of an insulin mimetic peptide by disulfide bridge modifications / $c M. Lubos, J. Pícha, I. Selicharová, J. Žák, M. Buděšínský, K. Mitrová, L. Žáková, J. Jiráček
- 520 9_
- $a Insulin is a peptide responsible for regulating the metabolic homeostasis of the organism; it elicits its effects through binding to the transmembrane insulin receptor (IR). Insulin mimetics with agonistic or antagonistic effects toward the receptor are an exciting field of research and could find applications in treating diabetes or malignant diseases. We prepared five variants of a previously reported 20-amino acid insulin-mimicking peptide. These peptides differ from each other by the structure of the covalent bridge connecting positions 11 and 18. In addition to the peptide with a disulfide bridge, a derivative with a dicarba bridge and three derivatives with a 1,2,3-triazole differing from each other by the presence of sulfur or oxygen in their staples were prepared. The strongest binding to IR was exhibited by the peptide with a disulfide bridge. All other derivatives only weakly bound to IR, and a relationship between increasing bridge length and lower binding affinity can be inferred. Despite their nanomolar affinities, none of the prepared peptide mimetics was able to activate the insulin receptor even at high concentrations, but all mimetics were able to inhibit insulin-induced receptor activation. However, the receptor remained approximately 30% active even at the highest concentration of the agents; thus, the agents behave as partial antagonists. An interesting observation is that these mimetic peptides do not antagonize insulin action in proportion to their binding affinities. The compounds characterized in this study show that it is possible to modulate the functional properties of insulin receptor peptide ligands using disulfide mimetics.
- 650 12
- $a inzulin $x metabolismus $7 D007328
- 650 12
- $a receptor inzulinu $7 D011972
- 650 _2
- $a disulfidy $x chemie $7 D004220
- 650 _2
- $a peptidy $x chemie $7 D010455
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Pícha, Jan $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Praha, Czech Republic
- 700 1_
- $a Selicharová, Irena $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Praha, Czech Republic
- 700 1_
- $a Žák, Jíří $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Praha, Czech Republic
- 700 1_
- $a Buděšínský, Miloš $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Praha, Czech Republic
- 700 1_
- $a Mitrová, Katarína $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Praha, Czech Republic
- 700 1_
- $a Žáková, Lenka $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Praha, Czech Republic
- 700 1_
- $a Jiráček, Jiří $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Praha, Czech Republic
- 773 0_
- $w MED00002886 $t Journal of peptide science : an official publication of the European Peptide Society $x 1099-1387 $g Roč. 29, č. 7 (2023), s. e3478
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36633503 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20230801132724 $b ABA008
- 999 __
- $a ok $b bmc $g 1963405 $s 1197224
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 29 $c 7 $d e3478 $e 20230125 $i 1099-1387 $m Journal of peptide science $n J Pept Sci $x MED00002886
- GRA __
- $a MR/R009066/1 $p Medical Research Council $2 United Kingdom
- LZP __
- $a Pubmed-20230718